KR102763004B1 - 흑색종의 검출 방법 - Google Patents

흑색종의 검출 방법 Download PDF

Info

Publication number
KR102763004B1
KR102763004B1 KR1020197038285A KR20197038285A KR102763004B1 KR 102763004 B1 KR102763004 B1 KR 102763004B1 KR 1020197038285 A KR1020197038285 A KR 1020197038285A KR 20197038285 A KR20197038285 A KR 20197038285A KR 102763004 B1 KR102763004 B1 KR 102763004B1
Authority
KR
South Korea
Prior art keywords
expression level
hla
cflar
melanoma
normalized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197038285A
Other languages
English (en)
Korean (ko)
Other versions
KR20200030034A (ko
Inventor
어빈 모들린
마크 키드
이그나트 드로즈도브
Original Assignee
리퀴드 바이옵시 리서치 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리퀴드 바이옵시 리서치 엘엘씨 filed Critical 리퀴드 바이옵시 리서치 엘엘씨
Publication of KR20200030034A publication Critical patent/KR20200030034A/ko
Application granted granted Critical
Publication of KR102763004B1 publication Critical patent/KR102763004B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
KR1020197038285A 2017-05-25 2018-05-21 흑색종의 검출 방법 Active KR102763004B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
US62/511,058 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (2)

Publication Number Publication Date
KR20200030034A KR20200030034A (ko) 2020-03-19
KR102763004B1 true KR102763004B1 (ko) 2025-02-04

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038285A Active KR102763004B1 (ko) 2017-05-25 2018-05-21 흑색종의 검출 방법

Country Status (14)

Country Link
US (2) US20180340934A1 (enExample)
EP (1) EP3631017B1 (enExample)
JP (1) JP7227964B2 (enExample)
KR (1) KR102763004B1 (enExample)
CN (1) CN111315897B (enExample)
AU (1) AU2018273844B2 (enExample)
BR (1) BR112019024481A2 (enExample)
CA (1) CA3064732A1 (enExample)
DK (1) DK3631017T3 (enExample)
ES (1) ES2920288T3 (enExample)
IL (1) IL270787B2 (enExample)
MX (1) MX2019014026A (enExample)
PL (1) PL3631017T3 (enExample)
WO (1) WO2018217627A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024481A2 (pt) 2017-05-25 2020-07-14 Liquid Biopsy Research LLC métodos para detecção de melanoma
US20210108259A1 (en) 2019-10-10 2021-04-15 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614946A1 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Biomarkers for melanoma
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
EP2080140B1 (en) * 2006-11-03 2013-04-24 Baylor Research Institute Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
US20110091384A1 (en) * 2009-10-13 2011-04-21 The Johns Hopkins University Biomarker for identification of melanoma tumor cells
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN104470920A (zh) * 2012-07-03 2015-03-25 通益制药有限公司 固态形式的维罗菲尼胆碱盐
AU2015317893B2 (en) * 2014-09-15 2021-05-20 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
BR112019024481A2 (pt) 2017-05-25 2020-07-14 Liquid Biopsy Research LLC métodos para detecção de melanoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Clin Aesthet Dermatol, 7(6): 13-24 (2014.06.)
J Clin Invest, 126(9): 3447-3452 (2016.09.01.)

Also Published As

Publication number Publication date
DK3631017T3 (da) 2022-06-20
JP7227964B2 (ja) 2023-02-22
EP3631017A1 (en) 2020-04-08
MX2019014026A (es) 2020-08-03
PL3631017T3 (pl) 2022-09-26
WO2018217627A1 (en) 2018-11-29
IL270787B2 (en) 2023-08-01
AU2018273844A1 (en) 2019-12-19
JP2020524524A (ja) 2020-08-20
US20180340934A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
ES2920288T3 (es) 2022-08-02
IL270787B1 (en) 2023-04-01
EP3631017B1 (en) 2022-03-23
CN111315897B (zh) 2024-10-22
KR20200030034A (ko) 2020-03-19
US12399179B2 (en) 2025-08-26
IL270787A (en) 2020-01-30
CN111315897A (zh) 2020-06-19
AU2018273844B2 (en) 2024-11-14
US20230022236A1 (en) 2023-01-26
CA3064732A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
KR101421326B1 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
US12366575B2 (en) Chemical compositions and methods of use
CN101258249A (zh) 检测黑素瘤的方法和试剂
CN114127314A (zh) 用于对乳腺癌的亚型(Subtype)进行鉴别或者分类的鉴别标志物遗传基因组、方法和套件
US12399179B2 (en) Chemical compositions and methods of use
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
JP2003259877A (ja) 肝線維症疾患マーカーおよびその利用
KR20190126812A (ko) 질환 진단용 바이오마커
CN100516876C (zh) 用于诊断肾细胞癌(rcc)和其他实体瘤的方法
KR102001153B1 (ko) 유방암 예후 예측용 조성물 및 방법
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
CN101827948A (zh) 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记
JP2003245082A (ja) 糸球体硬化症の疾患マーカーおよびその利用
HK40072692A (en) Distinguishing marker gene set, method and kit each for distinguishing or classifying subtype of breast cancer
HK1141723A (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin
HK1084696A (en) Prognostic for hematological malignancy
JP2002345492A (ja) 新規遺伝子及びそれにコードされる蛋白質
JP2003245081A (ja) 新規遺伝子及びそれにコードされる蛋白質
JP2003135080A (ja) 新規遺伝子及びそれにコードされる蛋白質

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240122

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241025

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250131

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250131

End annual number: 3

Start annual number: 1

PG1601 Publication of registration